Next Generation Payloads for ADCs

The clinical success of gemtuzumab ozogamicin, brentuximab vedotin and ado-trastuzumab emtansine has spurred significant investment into new ADC payloads that may expand the utility of ADC technology. Innovations in the past 5–10 years have resulted in the identification of new payloads that are overcoming resistance mechanisms, showing efficacy against slow growing tumors, and enabling the use of biomarkers to better understand ADC PK/PD relationships. Moreover, ADC technology is now enabling the delivery of steroids, anti-inflammatory agents, and anti-infectives to specific cell types.